<DOC>
	<DOCNO>NCT01812642</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics ( explores body drug ) JNJ-37822681 participant stable schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) .</brief_summary>
	<brief_title>A Pharmacokinetics Study Evaluate Safety Tolerability JNJ-37822681 Participants With Stable Schizophrenia</brief_title>
	<detailed_description>This double-blind ( neither physician participant know treatment participant receives ) , multi-center ( conducted one center ) , randomize ( treatment group assign chance ) , multiple-dose titration study JNJ-37822681 participant stable schizophrenia . The total study duration approximately 8 week per participant , consist 4 part : Screening ( , 21 day study commences Day 1 ) ; Double-blind treatment ( 14 day ) ; Follow-up ( 7 14 day last dose administration ) . Participants randomly assign treatment ascend dose level JNJ-37822681 daily twice daily . Efficacy primarily evaluate Positive Negative Syndrome Scale Clinical Global Impression-Severity scale . Safety Barnes Akathisia Rating Scale , Abnormal Involuntary Movement Scale Simpson Angus Rating Scale . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>N- ( 1- ( 3,4-difluorobenzyl ) piperidin-4-yl ) -6- ( trifluoromethyl ) pyridazin-3-amine</mesh_term>
	<criteria>Have schizophrenia diagnosis Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSMIV ) know history schizophrenia least 12 month refer psychiatrist Positive Negative Syndrome Scale score Screening le 70 Body Mass Index ( BMI ) 18 35 kilogram divide square meter inclusive ( BMI =weight per square height ) Female participant must meet one follow : postmenopausal ( amenorrhea least 12 month Follicle Stimulating Hormone level great 40 milliinternational unit ( MIU ) per milliliter Screening ) , surgically sterile ( hysterectomy bilateral oophorectomy , tubal ligation otherwise incapable pregnancy ) Any medical condition could potentially alter absorption , metabolism excretion study medication , Crohn 's ( serious inflammation part gastrointestinal tract ) disease , liver disease , renal disease Relevant history significant and/or unstable cardiovascular , respiratory , neurologic ( include seizure significant cerebrovascular ) , renal , hepatic , endocrine immunologic disease History neuroleptic malignant syndrome Female participant childbearing potential Significant risk suicidal violent behavior</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>JNJ-37822681</keyword>
	<keyword>Placebo</keyword>
</DOC>